Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer

Cancer Research

Volumn 61, Issue 21, 2001, Pages 7908-7912

  Brichory, Franck ^a   Le Naour, Francois ^a   Hanash, Samir ^a   Giordano, Thomas ^a   Beer, David ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GENE PRODUCT; PROTEIN GENE PRODUCT 9.5; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOBLOTTING; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BLOTTING, WESTERN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; THIOLESTER HYDROLASES; UBIQUITIN THIOLESTERASE;

EID: 0035503380     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients
2. New paths in human cancer serology
3. Infrequent presence of anti-c-Myc antibodies and absence of-c-Myc oncoprotein in sera from lung cancer patients
4. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: Association with improved survival
5. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma
6. Antinuclear antibodies as potential markers of lung cancer
7. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer
8. Natural autoantibody to MUCI is a prognostic indicator for non-small cell lung cancer
9. Pathogenic autoantibodies to neuronal proteins in neurological disorders
10. New Purkinje cell antibody (PCA-2): Marker of lung cancer-related neurological autoimmunity
11. Autoantibodies in paraneoplastic neurological syndrome
12. Autoimmunity in paraneoplastic neurological syndromes
13. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients
14. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies
15. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer-a quantitative Western blot analysis
16. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival
17. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes
18. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes
19. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome
20. Serum levels of interleukin 6 in patients with lung cancer
21. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer
22. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase
23. Molecular cloning of cDNA coding for human PGP 9.5 protein. A novel cytoplasmic marker for neurones and neuroendocrine cells
24. Immunohistochemical markers of small cell carcinoma and related neuroendocrine tumours of the lung
25. Serial analysis of gene expression in non-small cell lung cancer
26. Identification of β-tubulin isoforms as tumor antigens in neuroblastoma
27. Two-dimensional polyacrylamide gel electrophoresis of proteins
28. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: A method for the removal of silver ions to enhance sensitivity
29. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer
30. The ubiquitin system
31. The ubiquitin -proteasome pathway in cancer
32. Ubiquitin-dependent protein degradation
33. Chromogranin A gene expression in non-small cell lung carcinomas
34. Neural markers in carcinoma of the lung
35. PGP9.5 as a prognostic factor in pancreatic cancer
36. p53 antibodies in the sera of patients with various types of cancer: A review
37. An immune response manifested by common occurrence of annexins I and II autoantibodies and high circulating levels of interleukin 6 in lung cancer